Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > keep the enthusiasm in check

<< Previous

Bullboard Posts

Next >>

Comment by askretkaon Mar 27, 2023 6:20am

231 Views

Post# 35361772

RE:keep the enthusiasm in check

That drug your referring to was combined with FOLFIRINOX in latest trial a much more toxic drug than what Pelareorep is combining with and requires a ECOG of 0 or 1.
--------------------------------------
If you remember KOL the panel they said that they would have no problem putting patients of ECOG of 2 in the trial with pelareorep because of the excellent safety profile.
We're going to be able to treat a lot more Pancreatic patients if it works of course but it's looking fabulous so far.
Cheers!!!

<< Previous

Bullboard Posts

Next >>

10 common investing mistakes to avoid